Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of renal carcinoma, and potentially other cancers.
Ability to understand and willingness to sign a witnessed, informed consent and authorization for the release of health information. Patients with a diagnosis of relapsed Stage IV renal cell cancer that are medically unresponsive to prior treatment or surgically unresectable and with metastases that fall within the PET/CT field-of-view that can include the heart. Being considered for systemic therapy with Sunitinib
Exclusion Criteria:
Women who are pregnant, breast-feeding, or of childbearing potential and not using birth control Having no telephone or a reliable way in which study personal can contact them Subjects who are claustrophobic and cannot tolerate imaging procedures Subjects who weigh > 350 lb. (upper weight limit of scanner beds)
